News
Some everyday meds may quietly harm your heart. A cardiologist reveals 5 common drugs that could pose hidden risks to your cardiovascular health.
The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...
Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...
The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...
Biocon Biologics collaborates with Malaysia's National Cancer Society to launch a Patient Assistance Program, providing affordable biosimilars like Trastuzumab to underserved cancer patients and ...
Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at ...
3d
MedPage Today on MSNUpfront T-DXd Combo Nearly Doubles PFS in HER2-Positive Breast CancerAt the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...
Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.
A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...
Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results